Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer

Eitemau Tebyg

• Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
  gan: Wang, Wenxian, et al.
  Cyhoeddwyd: (2016)
• Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
  gan: Wang, Huan, et al.
  Cyhoeddwyd: (2014)
• Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
  gan: Wang, Jun, et al.
  Cyhoeddwyd: (2016)
• Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
  gan: Wang, Huan, et al.
  Cyhoeddwyd: (2014)
• The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
  gan: Chen, Dongfang, et al.
  Cyhoeddwyd: (2019)